Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection

Core Insights - Tevogen Bio Holdings Inc. estimates the risk-adjusted Net Present Value (rNPV) for its product TVGN 116, aimed at liver cancer prevention in high-risk chronic Hepatitis B patients, to exceed approximately $325 million in the US alone [1][3] - The cumulative 5-year top-line revenue forecast for TVGN 116 is projected to be around $6.5 billion, reflecting the company's innovative and efficient drug development model [2] Financial Projections - The current rNPV for TVGN 116 is based on the understanding of unmet medical needs and the competitive landscape, with adjustments made at each milestone in the product development lifecycle [3] - Tevogen's progress with its first clinical-stage product, TVGN 489, demonstrates the rapid achievement of development milestones [3] Strategic Outlook - The company’s drug development model is positioned as a potential blueprint for sustainable medical innovation in the future [2]